Carteolol
Carteolol is a non-selective beta blocker used to treat glaucoma.
![]() | |
Clinical data | |
---|---|
Trade names | Ocupress |
AHFS/Drugs.com | Micromedex Detailed Consumer Information |
MedlinePlus | a601078 |
Pregnancy category |
|
Routes of administration | Eye drops |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | 85% |
Metabolism | Hepatic, active with 8-hydrocarteolol |
Elimination half-life | 6–8 hours |
Excretion | Renal (50-70%) |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank |
|
ChemSpider |
|
UNII | |
KEGG |
|
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C16H24N2O3 |
Molar mass | 292.379 g·mol−1 |
3D model (JSmol) | |
Chirality | Racemic mixture |
| |
| |
(verify) |
It has been found to act as a serotonin 5-HT1A and 5-HT1B receptor antagonist in addition to being a beta blocker.[1]
It was patented in 1972 and approved for medical use in 1980.[2]
Brand names
Brand names include Cartrol, Ocupress, Teoptic, Arteolol, Arteoptic, Calte, Cartéabak, Carteol, Cartéol, Cartrol, Elebloc, Endak, Glauteolol, Mikelan, Poenglaucol, and Singlauc.
gollark: They never shall.
gollark: CB hatchlings in the AP? Madness.
gollark: Probably won't, even.
gollark: It *might not* die.
gollark: * is
References
- Langlois M, Brémont B, Rousselle D, Gaudy F (1993). "Structural analysis by the comparative molecular field analysis method of the affinity of beta-adrenoreceptor blocking agents for 5-HT1A and 5-HT1B receptors". Eur. J. Pharmacol. 244 (1): 77–87. doi:10.1016/0922-4106(93)90061-d. PMID 8093601.
- Fischer, Jnos; Ganellin, C. Robin (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 460. ISBN 9783527607495.
External links
- El-Kamel A, Al-Dosari H, Al-Jenoobi F (2006). "Environmentally responsive ophthalmic gel formulation of carteolol hydrochloride". Drug Deliv. 13 (1): 55–9. doi:10.1080/10717540500309073. PMID 16401594.
- Kuwahara K, Oizumi N, Fujisawa S, Tanito M, Ohira A (2005). "Carteolol hydrochloride protects human corneal epithelial cells from UVB-induced damage in vitro". Cornea. 24 (2): 213–20. doi:10.1097/01.ico.0000141232.41343.9d. PMID 15725891.
- Trinquand C, Romanet J, Nordmann J, Allaire C (2003). "[Efficacy and safety of long-acting carteolol 1% once daily. A double-masked, randomized study]". J Fr Ophtalmol. 26 (2): 131–6. PMID 12660585.
Sympathomimetics |
| ||||||
---|---|---|---|---|---|---|---|
Parasympathomimetics |
| ||||||
Carbonic anhydrase inhibitors/ (sulfonamides) | |||||||
Beta blocking agents | |||||||
Prostaglandin analogues (F2α) |
| ||||||
Other agents |
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.